Serum progesterone and estradiol in pregnant women selected for progestagen treatment.
Patients with two or more previous spontaneous second trimester abortions and vaginal cytology indicating a poor progestational response in current pregnancies were selected for treatment with Provera (medroxyprogesterone acetate) and/or Delalutin (17 alpha-hydroxyprogesterone caproate). Serum was examined serially for progesterone (P) and estradiol (E) by radioimmunoassay. Serum from 174 untreated patients with no known complications ranging from 6--40 weeks gestation provided normal distribution data. Of 14 progestagen-treated patients, four aborted during the second trimester. These all had chronically low (greater than 50% of observations were less than 1 standard deviation of the normal population) or falling P/E ratios. The rest delivered normal full-term infants although five of the 10 had chronically low P, seven had chronically low P/E ratios, and in one other P/E was falling. Chronically high E contributed to the low P/E ratio in three cases. Thus, these selected cases with poor obstetrical histories demonstrated steroid patterns outside the +/- 1 standard deviation range, although the steroid levels were still within the normal range. Serum progesterone and estradiol analysis may eventually be useful in identifying patients who will best respond to progestagen treatment.
D000026:Abortion, Habitual / Q000517:prevention & control*; D000033:Abortion, Threatened / Q000517:prevention & control*; D004958:Estradiol / Q000097:blood*; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood*; D011863:Radioimmunoassay
D006908:Hydroxyprogesterones; D011374:Progesterone; D004958:Estradiol; D008525:Medroxyprogesterone